Teva Pharmaceutical Industries Ltd Stock Price Declines
Teva Pharmaceutical Industries Ltd has experienced a decline in its stock price over the past few months, with a recent low point in April.
Company Overview
Teva Pharmaceutical Industries Ltd operates as a global pharmaceutical player, developing and marketing both generic and branded human pharmaceuticals.
Industry Developments
Recent news in the industry has focused on biosimilars, with Biocon Biologics securing EU approval for two biosimilars, Vevzuo and Evfraxy.
Potential Implications for Teva
This development may have implications for Teva’s business, as the company competes in the same market.
Additional Industry Developments
Biocon has announced plans to file for regulatory approvals of generic versions of Novo Nordisk’s Ozempic and Wegovy in key markets, including Canada, which may impact Teva’s sales.
Key Markets Affected
- Canada
Regulatory Approvals
- Biocon Biologics has secured EU approval for two biosimilars, Vevzuo and Evfraxy.
- Biocon plans to file for regulatory approvals of generic versions of Novo Nordisk’s Ozempic and Wegovy in key markets.